[lu-177]-pnt2002,abiraterone,enzalutamide
pfizer,astellas,point biopharma,janssen
['splash', 'crpc', '$pnt']
$pnt [15s. delayed]: issued press release on september 10, 03:05:00: point biopharma provides updated efficacy and safety data from the lead-in cohort of the phase 3 splash trial in mcrpc at esmo congress 2022 
Flash Alert is a low-latency financial news service which sources SEC, press releases, credible news sources to get your news about stocks in near real-time